Monika Sarkar1, Melissa Wellons2, Marcelle I Cedars3, Lisa VanWagner4, Erica P Gunderson5, Veeral Ajmera1, Laura Torchen6, David Siscovick7, J Jeffrey Carr8, James G Terry8, Mary Rinella4, Cora E Lewis9, Norah Terrault1. 1. Division of Gastroenterology and Hepatology, University of California, San Francisco, California, USA. 2. Division of Diabetes, Endocrinology, and Metabolism, Vanderbilt University Medical Center, Nashville, Tennessee, USA. 3. Department of Obstetrics and Gynecology, University of California, San Francisco, California, USA. 4. Division of Gastroenterology and Hepatology, Northwestern University, Chicago, Illinois, USA. 5. Kaiser Permanente Division of Research, Oakland, California, USA. 6. Division of Pediatric Endocrinology, Northwestern University, Chicago, Illinois, USA. 7. New York Academy of Medicine, New York, New York, USA. 8. Department of Radiology, Vanderbilt University Medical Center, Nashville, Tennessee, USA. 9. Division of Preventive Medicine, University of Alabama Birmingham, Birmingham, Alabama, USA.
Abstract
OBJECTIVES: Young women with hyperandrogenism have high risk of metabolic co-morbidities, including increased risk of nonalcoholic fatty liver disease (NAFLD). Whether testosterone (the predominant androgen) is associated with NAFLD independent of metabolic co-factors is unclear. Additionally, whether testosterone confers increased risk of NAFLD in women without hyperandrogenism is unknown. METHODS: Among women in the prospective population-based multicenter Coronary Artery Risk Development in Young Adults (CARDIA) study, we assessed whether free testosterone levels measured at Year 2 (1987-1988) were associated with prevalent NAFLD at Year 25 (2010-2011) (n=1052). NAFLD was defined using noncontrast abdominal CT scan with liver attenuation≤40 Hounsfield units after excluding other causes of hepatic fat. The association of free testosterone with prevalent NAFLD was assessed by logistic regression. RESULTS: Increasing quintiles of free testosterone were associated with prevalent NAFLD at Year 25 (adjusted odds ratio (AOR) 1.25, 95% confidence interval (CI) 1.04-1.50, P=0.015), independent of insulin resistance, body mass index, waist circumference, and serum lipids. Importantly, the association persisted among n=955 women without androgen excess (AOR 1.27, 95% CI 1.05-1.53, P=0.016). Visceral adipose tissue (VAT) volume partially mediated the association of free testosterone with NAFLD (mediating effect 41.0%, 95% CI 22-119%). CONCLUSIONS: Increasing free testosterone is associated with prevalent NAFLD in middle age, even in women without androgen excess. Visceral adiposity appears to play an important role in the relationship between testosterone and NAFLD in women. Testosterone may provide a potential novel target for NAFLD therapeutics, and future studies in pre-menopausal women should consider the importance of testosterone as a risk factor for NAFLD.
OBJECTIVES: Young women with hyperandrogenism have high risk of metabolic co-morbidities, including increased risk of nonalcoholic fatty liver disease (NAFLD). Whether testosterone (the predominant androgen) is associated with NAFLD independent of metabolic co-factors is unclear. Additionally, whether testosterone confers increased risk of NAFLD in women without hyperandrogenism is unknown. METHODS: Among women in the prospective population-based multicenter Coronary Artery Risk Development in Young Adults (CARDIA) study, we assessed whether free testosterone levels measured at Year 2 (1987-1988) were associated with prevalent NAFLD at Year 25 (2010-2011) (n=1052). NAFLD was defined using noncontrast abdominal CT scan with liver attenuation≤40 Hounsfield units after excluding other causes of hepatic fat. The association of free testosterone with prevalent NAFLD was assessed by logistic regression. RESULTS: Increasing quintiles of free testosterone were associated with prevalent NAFLD at Year 25 (adjusted odds ratio (AOR) 1.25, 95% confidence interval (CI) 1.04-1.50, P=0.015), independent of insulin resistance, body mass index, waist circumference, and serum lipids. Importantly, the association persisted among n=955 women without androgen excess (AOR 1.27, 95% CI 1.05-1.53, P=0.016). Visceral adipose tissue (VAT) volume partially mediated the association of free testosterone with NAFLD (mediating effect 41.0%, 95% CI 22-119%). CONCLUSIONS: Increasing free testosterone is associated with prevalent NAFLD in middle age, even in women without androgen excess. Visceral adiposity appears to play an important role in the relationship between testosterone and NAFLD in women. Testosterone may provide a potential novel target for NAFLD therapeutics, and future studies in pre-menopausal women should consider the importance of testosterone as a risk factor for NAFLD.
Authors: Brent A Neuschwander-Tetri; Jeanne M Clark; Nathan M Bass; Mark L Van Natta; Aynur Unalp-Arida; James Tonascia; Claudia O Zein; Elizabeth M Brunt; David E Kleiner; Arthur J McCullough; Arun J Sanyal; Anna Mae Diehl; Joel E Lavine; Naga Chalasani; Kris V Kowdley Journal: Hepatology Date: 2010-09 Impact factor: 17.425
Authors: G R Cutter; G L Burke; A R Dyer; G D Friedman; J E Hilner; G H Hughes; S B Hulley; D R Jacobs; K Liu; T A Manolio Journal: Control Clin Trials Date: 1991-02
Authors: L Nikolaenko; Y Jia; C Wang; M Diaz-Arjonilla; J K Yee; S W French; P Y Liu; S Laurel; C Chong; K Lee; Y Lue; W N P Lee; R S Swerdloff Journal: Endocrinology Date: 2013-11-26 Impact factor: 4.736
Authors: Mariana Lazo; Ruben Hernaez; Mark S Eberhardt; Susanne Bonekamp; Ihab Kamel; Eliseo Guallar; Ayman Koteish; Frederick L Brancati; Jeanne M Clark Journal: Am J Epidemiol Date: 2013-05-23 Impact factor: 4.897
Authors: Monika Sarkar; Norah Terrault; Wesley Chan; Marcelle I Cedars; Heather G Huddleston; Caroline C Duwaerts; Dana Balitzer; Ryan M Gill Journal: Liver Int Date: 2019-11-12 Impact factor: 5.828